Skip to Content

Aditxt Inc Ordinary Shares ADTX

Morningstar Rating
$1.99 −0.02 (1.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ADTX is trading at a 117% premium.
Price
$2.02
Fair Value
$4.54
Uncertainty
Extreme
1-Star Price
$19.61
5-Star Price
$2.92
Economic Moat
Vyx
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADTX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.01
Day Range
$1.962.02
52-Week Range
$1.9568.08
Bid/Ask
$1.97 / $2.09
Market Cap
$3.31 Mil
Volume/Avg
15,847 / 349,344

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1.19
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
47

Valuation

Metric
ADTX
Price/Earnings (Normalized)
Price/Book Value
0.33
Price/Sales
1.19
Price/Cash Flow
Price/Earnings
ADTX

Financial Strength

Metric
ADTX
Quick Ratio
0.03
Current Ratio
0.09
Interest Coverage
−3.44
Quick Ratio
ADTX

Profitability

Metric
ADTX
Return on Assets (Normalized)
−197.46%
Return on Equity (Normalized)
−1,170.27%
Return on Invested Capital (Normalized)
−242.61%
Return on Assets
ADTX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRXwdsxxrjQhdf$590.5 Bil
VRTX
Vertex Pharmaceuticals IncJhyynnvqdWxkqlns$113.9 Bil
REGN
Regeneron Pharmaceuticals IncLqmrxgrpJhnxgt$106.5 Bil
MRNA
Moderna IncBryhmhsShspn$58.7 Bil
BNTX
BioNTech SE ADRDfpndbwtXzttz$22.7 Bil
ARGX
argenx SE ADRClszmxhtQdh$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncJwfynpkrmYgyygp$19.0 Bil
BMRN
Biomarin Pharmaceutical IncVwjnnmwqRrwcs$14.1 Bil
INCY
Incyte CorpZzzcyfqgXcwvq$12.8 Bil
TECH
Bio-Techne CorpGgcyvrynrvDyzvzxr$12.4 Bil

Sponsor Center